Charles River Laboratories International CRL

Charles River Laboratories International, Inc. is a leading global provider of non‑clinical drug development services and products. The company supports clients from early‑stage discovery through safety assessment and manufacturing by offering research models, associated services, discovery and safety testing, and microbial and biologics solutions. Its integrated portfolio enables pharmaceutical and biotechnology firms to accelerate drug development while reducing costs and improving efficiency.

The company generates revenue primarily through the sale of research models and related services, discovery and safety assessment contracts, and microbial and biologics testing and manufacturing solutions. In 2025, total revenue reached $4.0 billion, with the Discovery and Safety Assessment segment contributing the largest share followed by Manufacturing Solutions and Research Models and Services.

The company operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

• Research Models and Services: This segment supplies purpose‑bred rodents, large research models, and related services such as insourcing solutions, genetically engineered models and services, research animal diagnostic services, and cell solutions to support drug discovery and development activities worldwide.
• Discovery and Safety Assessment: This segment provides outsourced drug discovery services, including target identification and lead optimization, and regulated safety assessment services such as toxicology, pathology, safety pharmacology, and bioanalysis for drugs, vaccines, chemicals, and medical devices across multiple therapeutic areas.
• Manufacturing Solutions: This segment comprises Microbial Solutions, which offers endotoxin, rapid microbial detection, and microbial identification testing, and Biologics Solutions, which provides biologics testing services and contract development and manufacturing for cell and gene therapies.

Charles River Laboratories International, Inc. holds a leading position in the outsourced non‑clinical drug development market, competing with a range of public and private firms in each segment. Its competitive advantages stem from a broad scientifically differentiated portfolio, deep scientific expertise, global footprint, commitment to animal welfare, and ability to deliver integrated, customized solutions that enhance client productivity and speed to market.

The company serves a diverse client base that includes major global pharmaceutical companies, biotechnology firms, agricultural and industrial chemical companies, life science and veterinary medicine companies, medical device and diagnostic companies, contract research and contract manufacturing organizations, as well as leading hospitals, academic institutions, and government agencies worldwide.